Search Results - "Arteaga, C. L."

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition by Rexer, B N, Ham, A-J L, Rinehart, C, Hill, S, de Matos Granja-Ingram, N, González-Angulo, A M, Mills, G B, Dave, B, Chang, J C, Liebler, D C, Arteaga, C L

“…Despite the initial effectiveness of the tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventually relapse after…”
Get full text

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer by Dillon, L M, Bean, J R, Yang, W, Shee, K, Symonds, L K, Balko, J M, McDonald, W H, Liu, S, Gonzalez-Angulo, A M, Mills, G B, Arteaga, C L, Miller, T W

“…Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate…”
Get full text

The Epidermal Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia by ARTEAGA, Carlos L

“…Approximately two decades ago, the epidermal growth factor receptor (EGFR) was discovered to be the proto-oncogene of the mutant, constitutively active…”
Get full text

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 by Chakrabarty, A, Rexer, B N, Wang, S E, Cook, R S, Engelman, J A, Arteaga, C L

“…Hyperactivation of phosphatidylinositol-3 kinase (PI3K) can occur as a result of somatic mutations in PIK3CA , the gene encoding the p110α subunit of PI3K. The…”
Get full text

Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes by Ju, J-h, Oh, S, Lee, K-m, Yang, W, Nam, K S, Moon, H-G, Noh, D-Y, Kim, C G, Park, G, Park, J B, Lee, T, Arteaga, C L, Shin, I

“…Cytokeratin19 (KRT19) is widely used as a biomarker for the detection of disseminated tumors. Using an LC-MS/MS proteomics approach, we found that KRT19 was…”
Get full text

Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression by MURAOKA-COOK, R. S, SHIN, I, YI, J. Y, EASTERLY, E, BARCELLOS-HOFF, M. H, YINGLING, J. M, ZENT, R, ARTEAGA, C. L

“…We have examined the effects of transforming growth factor-beta (TGFβ) signaling on mammary epithelial cell survival. Transgenic mice expressing an active…”
Get full text

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial by Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

“…The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and…”
Get full text

Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators by Wang, S E, Yu, Y, Criswell, T L, DeBusk, L M, Lin, P C, Zent, R, Johnson, D H, Ren, X, Arteaga, C L

“…Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows…”
Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

“…The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line…”
Get full text

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

“…The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic…”
Get full text

Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta by Dumont, N, Arteaga, C L

“…The transforming growth factor (TGF)-betas are potent growth inhibitors of normal epithelial cells. In established tumor cell systems, however, the…”
Get full text

Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1 by Shin, I, Bakin, A V, Rodeck, U, Brunet, A, Arteaga, C L

“…The Forkhead family of transcription factors participates in the induction of death-related genes. In NMuMG and 4T1 mammary epithelial cells, transforming…”
Get full text

Inhibition of erbB Receptor (HER) Tyrosine Kinases as a Strategy to Abrogate Antiestrogen Resistance in Human Breast Cancer by Kurokawa, H, Arteaga, C L

“…It has been proposed that binding of ligand to the estrogen receptor (ER) releases its association with transcriptional corepressors, allowing the ER to…”
Get full text

EGF Receptor As a Therapeutic Target: Patient Selection and Mechanisms of Resistance to Receptor-Targeted Drugs by Arteaga, Carlos L

“…Emerging results from clinical trials of epidermal growth factor receptor (EGFR) inhibitors indicate good tolerability and at best modest to no clinical…”
Get full text

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials by André, F., Su, F., Solovieff, N., Hortobagyi, G., Chia, S., Neven, P., Bardia, A., Tripathy, D., Lu, Y.-S., Lteif, A., Taran, T., Babbar, N., Slamon, D., Arteaga, C.L.

“…The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy…”
Get full text

Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity : implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression by ARTEAGA, C. L, HURD, S. D, WINNIER, A. R, JOHNSON, M. D, FENDLY, B. M, FORBES, J. T

“…TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using…”
Get full text

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial by Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Rapael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., Solit, D.B.

“…HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients…”
Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

Get full text

Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β by ARTEAGA, C. L, KOLI, K. M, DUGGER, T. C, CLARKE, R

“…Overexpression of transforming growth factor (TGF)-beta has been reported in human breast carcinomas resistant to antiestrogen tamoxifen, but the role of…”
Get full text

Growth retardation and tumour inhibition by BRCA1 by Holt, Jeffrey T, Thompson, Marilyn E, Szabo, Csilla, Robinson-Benion, Cheryl, Arteaga, Carlos L, King, Mary-Claire, Jensen, Roy A

“…Inherited mutations in BRCA1 predispose to breast and ovarian cancer, but the role of BRCA1 in sporadic breast and ovarian cancer has previously been elusive…”
Get full text